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Abstract 
Colonization of the upper respiratory tract by pneumococcus is important both as a 
determinant of disease and for transmission into the population. The immunological 
mechanisms that contain pneumococcus during colonization are well studied in mice but 
remain unclear in humans. Loss of this control of pneumococcus following infection with 
influenza virus is associated with secondary bacterial pneumonia. We used a human 
challenge model with type 6B pneumococcus to show that acquisition of pneumococcus 
induced early degranulation of resident neutrophils and recruitment of monocytes to the 
nose. Monocyte function was associated with the clearance of pneumococcus. Prior nasal 
infection with live attenuated influenza virus induced inflammation, impaired innate immune 
function and altered genome-wide nasal gene responses to the carriage of pneumococcus. 
Levels of the cytokine CXCL10, promoted by viral infection, at the time pneumococcus was 
encountered were positively associated with bacterial load.  
 
Introduction 
Pneumonia is a major global health problem; it kills more children under 5 years of age than any 
other disease 1. The burden of disease is aggravated by old age, chronic lung disease, 
immunosuppression and viral co-infection. Secondary pneumonia following pandemic and seasonal 
influenza virus infection is a significant cause of mortality worldwide 2. 
Nasopharyngeal colonization by Streptococcus pneumoniae (Spn, pneumococcus) is common with 
40-95% of infants and 10-25% of adults colonised at any time 3. Such pneumococcal carriage is 
important as the pre-requisite of infection 4, the primary reservoir for transmission 5 and the 
predominant source of immunizing exposure and immunological boosting in both children and adults 
6,7.  
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Immune dysregulation caused by respiratory virus infection such as influenza leads to increased 
carriage load 8. Increased carriage load has been associated with pneumonia incidence and severity, 
as well as with within-household Spn transmission 5,9-11. The mechanisms and markers associated 
with this pathogen synergy have been difficult to study in human subjects due to the rapid nature of 
the disease. 
One safe way to simulate influenza infection in the nose is using Live Attenuated Influenza Vaccine 
(LAIV), consisting of cold-adapted influenza viruses. LAIV has been shown to affect the subsequent 
susceptibility to Spn and to lead to increased carriage load in murine models of infection and in 
vaccinated children 12,13. Furthermore, LAIV administration prior to Spn challenge led to 50% 
increase in Spn acquisition by molecular methods as well as 10-fold increase in nasopharyngeal 
bacterial load 14.  
In murine models of pneumococcal carriage, TH17-dependent recruitment of neutrophils and 
monocytes to the nasopharynx mediates immunological control and clearance 15-17. Influenza virus 
infection promotes Type I interferons which interfere with recruitment of these phagocytes, although 
IFN-ɣ is postulated to impair phagocytosis by macrophages through downregulation of the 
scavenger receptor MARCO 18-20. However, the precise immune mechanisms and gene regulators 
involved in the control and clearance of pneumococcal carriage in humans have not been revealed 
21. Moreover, how these mechanisms are altered during human influenza virus infection remains 
largely unknown.  
Systems biology approaches have allowed for the identification of immune mechanisms associated 
with protection from infectious diseases and with robust immune responses during vaccination 22-28. 
Here, we applied systems biology to nasal samples collected in the setting of human challenge with 
LAIV and Spn, to emulate nasal effects of influenza infection on Spn carriage. We identified for the 
first time in humans the key cellular mechanisms that control newly acquired pneumococcal carriage, 
and how they are disrupted following nasal influenza infection. 
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Results 
LAIV-induced inflammation leads to increased pneumococcal carriage load and acquisition 
In a double-blinded controlled randomized clinical trial, we administered LAIV (n=55) three days prior 
to Spn inoculation (day 0). To verify the requisite topical application for an effect on pneumococcal 
carriage, we administered tetravalent inactivated influenza vaccine (TIV) as a control (n=62). LAIV 
infection led to transiently increased pneumococcal acquisition at day 2 (60.0% vs. 40.3% by 
molecular methods in LAIV vs. control groups, respectively) 14. LAIV also increased Spn carriage 
load in the first 14 days following pneumococcal inoculation (Supplementary Fig. 1 and 14). We 
collected a series of nasal micro-biopsies and nasal lining fluid throughout the study to assess 
ongoing cellular and cytokine responses. Participants were grouped into those who did not become 
colonized following Spn challenge (carriage–) and those who did (carriage+), as determined by 
classical microbiology (Fig. 1a). To investigate whether LAIV-induced immune responses were 
associated with a predisposition to pneumococcal carriage, we measured concentrations of 30 
cytokines, and proteins including IL-1RA, in nasal lining fluid (Fig. 1b). At day 0, directly prior to Spn 
inoculation, LAIV significantly increased concentrations of twenty cytokines after multiple testing 
correction, including CXCL10 (IP-10), TNF, IL-10, IFN-ɣ and IL-15 (Fig. 1b and Supplementary Table 
1). In contrast, the control group did not show any significant increase in cytokine response at day 
0. Following Spn inoculation, Spn carriage in the absence of LAIV was associated with increased 
concentration of epidermal growth factor (EGF) at day 2 and decreased concentrations of IL-1RA at 
day 9 post Spn inoculation compared to baseline, neither of which remained significant after multiple 
testing correction. No other cytokines, including IL-17A or CCL2, were significantly altered by 
carriage alone (Fig. 1b).  
 
Even before bacterial inoculation, nasal inflammatory responses to LAIV differed between those who 
went on to become carrier and those who were protected from carriage (Fig. 1c). In particular, IL-10 
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was significantly increased in LAIV-vaccinated subjects who did not acquire Spn following 
inoculation (5.8-fold increase), but not in those who became carriers following inoculation (2.0-fold 
increase). In contrast, CXCL10 was significantly increased in subjects who went on to become 
carriers (2.4-fold increase), but not in those who remained carriage-negative (1.5-fold increase). 
Moreover, subjects with increased concentrations of CXCL10 before inoculation displayed higher 
pneumococcal load following Spn inoculation (Fig. 1d). This suggests that differences in the 
response to influenza virus are associated with secondary susceptibility to Spn. To test whether this 
was specific for LAIV infection, we measured CXCL10 in nasal washes from an independent cohort 
in which a subset of subjects had asymptomatic viral upper respiratory tract infection the week before 
Spn inoculation, which did not progress to symptomatic infection. These comprised rhinovirus 
(n=12), coronavirus (n=5), respiratory syncytial virus (n=2) and parainfluenzavirus (n=1) 29. The 
predominant virus, rhinovirus, was recently shown to associate with increased pneumococcal 
acquisition and transmission 30. In these virus-infected subjects, CXCL10 concentration was 
increased (Supplementary Fig. 2), and baseline CXCL10 concentration correlated with increased 
pneumococcal load also in this second cohort (Fig. 1e). Unfortunately, sample sizes were too small 
to further investigate in depth the effect of infection by the different viruses, which are likely to have 
divergent effects. Although the correlation was modest in this validation cohort suggesting that other 
host and environmental factors are involved, this is the first time a biomarker predicting Spn load 
has been identified. 
 
Early neutrophil degranulation in response to carriage is impaired by LAIV infection 
In murine models, neutrophil recruitment after onset of carriage contributes to control of the bacteria 
15. We observed pre-existing high numbers of neutrophils in the human nasal lining and 
pneumococcal carriage did not lead to significant further recruitment of neutrophils (Supplementary 
Fig. 3a,b). To investigate whether luminal neutrophils were involved in the early control of carriage, 
we measured myeloperoxidase (MPO) concentrations, a marker for neutrophil degranulation 31, in 
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nasal washes. Concentrations were increased (2.2-fold) at 2 days after challenge in control carriage+ 
but not carriage– individuals (Fig. 2a). This neutrophil activation was impaired in the LAIV group, 
who displayed high carriage load during early carriage and had increased acquisition compared to 
controls. Together, this suggests that neutrophil degranulation is important for the initial control of 
carriage. To investigate whether neutrophils were also impaired systemically following LAIV as 
reported during wild-type influenza infection 32, we isolated blood neutrophils before, and at three 
days after, LAIV administration from a subset of subjects. We confirmed that opsonophagocytic 
(OPK) killing of Spn by blood neutrophils was decreased following LAIV (Fig. 2b). This effect could 
be mimicked by the addition of TNF, but not CXCL10, to neutrophils from healthy donors in vitro, 
decreasing killing capacity in a dose-dependent manner (Fig. 2c,d). Nanostring expression analysis 
of 594 genes revealed 10 differentially expressed genes in blood neutrophils 3 days post LAIV 
(Supplementary Table 2). Among those were MAP4K2 (3.2-fold increase), which acts on the TNF 
signal transduction pathway 33, and the co-inhibitory receptor TIGIT (3.6-fold increase, Fig. 2e). 
TIGIT expression levels also negatively correlated with neutrophil killing capacity (r=-0.73, Fig. 2f). 
TIGIT is an “immune checkpoint” protein, which has been described to promote regulatory T cell 
(Treg cell) function 34, but its expression on neutrophils has not been previously appreciated. 
Incubation of whole blood with recombinant TNF increased TIGIT levels on neutrophil surface within 
30 minutes in a dose-dependent manner (Fig. 2g). 
Taken together, inflammation following LAIV impaired the response of nasal and systemic 
neutrophils to pneumococcus, which could be mimicked by addition of exogenous TNF to neutrophils 
and associated with an upregulation of TIGIT. 
 
Pneumococcal carriage-induced monocytes recruitment to the nose is impaired by LAIV 
infection 
Immunophenotyping revealed a significant recruitment of monocytes to the nose following 
establishment of carriage (Fig. 3a and Supplementary Fig. 4). Monocyte numbers increased as early 
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as 2 days following Spn inoculation, peaked at 9 days (median 4.8x increase) and remained elevated 
29 days post Spn inoculation. In contrast, there was no recruitment of CD3+ T cells to the nose 
(Supplementary Fig. 4b). LAIV infection prior to pneumococcal carriage impaired the recruitment of 
monocytes to the nose (Fig. 3a). Moreover, peak pneumococcal load associated with increased 
monocyte recruitment in the control group, but not the LAIV group (Fig. 3b,c). Indeed, for subjects in 
the control group with very low carriage densities, which were only detectable by molecular methods, 
no monocyte recruitment was observed (Supplementary Fig. 4c). This suggests that a minimum Spn 
load is required for sensing and monocyte recruitment and that LAIV infection interferes with this 
process. Although CCL2 (MCP-1) was not substantially induced following Spn carriage, its 
concentration correlated with numbers of monocytes at all timepoints (Supplementary Fig. 5a). 
Furthermore, stratification of individuals showed that those with increased CCL2 concentration at 
day 2 post Spn inoculation exhibit increased monocyte recruitment (Supplementary Fig. 5b). 
Concentrations of IL-6, IFN- and TNF also correlated with numbers of monocytes at each time point, 
but stratification of individuals did not reveal a differential recruitment of monocytes (Supplementary 
Fig. 5a,b). In a second, independent cohort that did not receive any vaccine, monocytes were 
increased at day 9 following Spn inoculation, which correlated with an increased CCL2 concentration 
in nasal fluid, validating these results (Supplementary Table 3 and Supplementary Fig. 5c).  
Thus, acquisition of pneumococcal carriage led to a recruitment of monocytes to the nasopharynx, 
a process that associated with pneumococcal load, CCL2 induction and that was inhibited by LAIV 
infection. 
Nasal responses associated with pneumococcal clearance are impaired by LAIV 
To assess anti-pneumococcal responses induced by carriage, we collected nasal cells 29 days post 
Spn inoculation and stimulated in vitro with heat-killed Spn and measured concentrations of 30 
cytokines in supernatant. An increased production (fold-change (FC) > 2 and q < 0.05 to 
unstimulated control) of TNF, MIP-1α, IL-10, IL-6 and GM-CSF upon restimulation was observed in 
the control carriage+ group (Fig. 4a and Supplementary Fig. 6a). In the LAIV carriage+ group, 
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however, this boosting of anti-pneumococcal cytokine responses by re-challenge was absent (Fig. 
4a and Supplementary Fig. 6a). The production of the above five cytokines correlated with decreased 
pneumococcal load at day 29 post Spn inoculation, suggesting these responses are involved in Spn 
clearance (Fig. 4b). To test whether monocytes/macrophages were the source of these cytokines 
we compared the cytokine signature from whole nasal cells with that from alveolar macrophages 
exposed to Spn in vitro (Fig. 4c). Relative cytokine production highly correlated between the two cell 
populations, suggesting that nasal monocytes/macrophages could be the source of these cytokines. 
This is supported by the observation that in carriers with low carriage load (only detectable by 
molecular methods), absence of monocyte recruitment associated with absent Spn-specific 
responses (Supplementary Fig. 6b). 
In conclusion, carriage led to increased responses of nasal cells to pneumococcal stimulation, which 
was potentially due to the infiltration of monocytes. This was impaired by prior LAIV infection and 
correlated with clearance of pneumococcal carriage (Supplementary Fig. 7). 
 
LAIV alters nasal gene expression responses to carriage 
To identify gene signatures associated with the observed responses to pneumococcal carriage and 
infection with LAIV, we performed RNA-sequencing on whole nasal cells at days -5, 2 and 9 from 
Spn inoculation (Fig. 5 and Supplementary Table 4). Carriage without LAIV induced 834 and 176 
differentially expressed genes (DEG) at day 2 and day 9, respectively (Fig. 5a). These genes were 
enriched for pathways associated with Gap junction trafficking and regulation (including GJA1, TJP1 
and multiple GJB) and degradation of the extracellular matrix (including COL17A1, COL12A1, 
LAMA3, KLK7). In the carriage– group, a smaller number of DEG was observed (161 and 248 at day 
2 and day 9, respectively). 
In the LAIV carriage+ group, 936 and 711 DEG were observed at day 2 and day 9, respectively. 
Surprisingly, despite the high concentrations of inflammatory cytokines observed in the LAIV 
carriage– group, only a relatively small number of DEG were observed at days 2 and 9 (126 and 
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153, respectively). DEG of carriage+ subjects receiving LAIV and DEG of carriage+ without LAIV 
showed very little overlap with only 38 DEG at day 2 and 2 DEG at day 9 in common. Very little 
overlap was observed at the pathway level between these groups, indicating LAIV alters the natural 
responses to pneumococcus (Fig. 5b and Supplementary Table 5). This could reflect transcriptome 
kinetics, such as observed in altered differentiation and cellular activation, or changes in cell 
migration to the nasal mucosa. 
The LAIV carriage+ group showed an enrichment for genes in the Toll-like receptor 3 (TLR3) 
signalling cascade, RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways and IFN-gamma 
signalling, which is in agreement with the induction of antiviral responses following LAIV vaccination 
35. Moreover, TLR4 signalling was also enriched in this group. The pneumococcal protein 
pneumolysin is sensed by TLR4 36 and it is possible that the increased pneumococcal load following 
LAIV vaccination led to increased pneumolysin sensing. O-linked glycosylation of mucins, which are 
used by Spn as a carbohydrate source for growth 37, was also enriched in the LAIV carriage+ group 
(including genes ST3GAL4, GALNT7, GCNT3, B4GALT5). ST3GAL4 is a sialyl transferase and 
cleavage of sialic acids by the influenza neuraminidase has previously been shown to promote 
pneumococcal growth 38. This finding supports a LAIV-mediated effect on pneumococcal growth 
through alterations of host factors. Common genes and pathways between the LAIV-vaccinated and 
control carriers include “Innate immune system” and “Signaling by interleukins” (IL1B, CLEC4E, 
CD55, IL1RN). In conclusion, the genome-wide transcriptomic response to pneumococcal carriage 
was substantially altered on both the gene and the pathway level by LAIV.  
 
Gene modules associated with recruitment of monocytes 
To identify sets of co-expressed genes post LAIV and carriage, we used CEMiTool on the baseline-
normalized data of LAIV and control groups, separately 39. This modular expression analysis 
revealed the genes that may act together or are similarly regulated during the immune responses to 
carriage and infection.  
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Genes in the control cohort were grouped into four co-expression modules, of which three were 
significantly enriched for known Reactome pathways (Supplementary information 1). Module M1 
was enriched in carriage+ at day 9 post Spn inoculation (Fig. 6a). Numbers of monocytes correlated 
with the average fold change count in this module, suggesting that these genes reflect the infiltration 
of monocytes ( Fig. 6b). To further investigate these monocytes, we performed gene set enrichment 
analysis on the Module M1 genes using list of genes from distinct monocyte subsets (Fig. 6c) 40. 
These genes were enriched for classical CD14+CD16– monocytes and not for other monocyte 
subsets. Moreover, this module was enriched for genes related to “chemokine receptors bind 
chemokines” and “interferon α/β signalling” (Fig. 6d). Type I interferon has been shown to be required 
for the clearance of pneumococcal carriage in murine models 41 and these findings suggest that their 
activity in monocytes might be critical for this. CEMiTool also integrates co-expression analysis with 
protein-protein interaction data. Expression of CXCL6 and its receptor CXCR2 were identified as 
hubs in this module M1 (Fig. 6e and Supp html file 1). CXCR2 engagement has been shown to 
induce attachment of monocytes to the endothelial layer, initiating chemotaxis, which suggests this 
interaction could contribute to monocyte recruitment 42. Module M3 was enriched in genes related to 
“extracellular matrix organization” and “collagen formation” (Fig. 7).  
 
For LAIV, we identified six distinct co-expression modules (Supplementary information 2), which 
were strongly enriched in genes related to “Diseases associated with O-glycosylation of proteins” 
(module M1), “Immunoregulatory interactions between a lymphoid and a non-Lymphoid cell” (module 
M3), “chemokine receptors bind chemokines” (module M4), as well as “interferon signalling” (module 
M5, Fig. 8). Indeed, the hubs of module M5 are well known type I interferon-related genes, such as 
ISG15, OAS1, OASL, IFIT1-3, and IFITM1. Altogether, our findings reveal that a strong local antiviral 
response is elicited in response to LAIV infection.  
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Discussion 
This study addresses fundamental questions about the immune responses that control and clear 
Spn carriage and how influenza infection can alter this control. By using for the first time a double 
experimental human challenge model with LAIV and Spn, we revealed that Spn carriage led to a 
quick degranulation of pre-existent nasal neutrophils in the human nose and recruitment of 
monocytes, promoting bacterial clearance. LAIV infection impaired these immune responses 
following carriage. LAIV is an attenuated influenza strain and wild-type influenza viruses might have 
even more pronounced effects on the host response to pneumococcus. Carriage in the absence of 
LAIV was associated with only limited inflammation, corroborating the view of Spn as a commensal 
bacterium that can asymptomatically colonize healthy adults 43. In contrast, robust pro-inflammatory 
cytokine responses were measured following LAIV at both the protein and gene expression level. 
Altogether, these results provide explanation for our previous report that LAIV increased acquisition 
of Spn and carriage load 14.  
In addition, our findings that LAIV led to impaired blood neutrophil killing capacity and that the 
addition of TNF, which was increased following LAIV, to neutrophils in vitro impaired their activity, 
highlights their crucial roles in susceptibility to secondary bacterial infection 44. The association of 
TIGIT in this impaired neutrophil function following influenza infection warrants further investigation 
as TIGIT-blocking therapeutics are currently being developed for cancer and HIV treatment 45.  
We identified CXCL10 as a marker for increased susceptibility to Spn and propose this should be 
further investigated as a potential therapeutic target for secondary bacterial infections associated 
with virus infections. Our data showed that individuals with higher concentrations of CXCL10 prior 
to Spn inoculation had higher bacterial load. In a previous study, children with pneumonia with viral 
and bacterial (predominantly pneumococcal) co-infection had increased amounts of CXCL10 
compared to children with just viral or bacterial pneumonia, which associated with disease severity 
46. Murine data suggests that CXCL10 plays a direct role during pneumonia. Mice with genetic 
ablation of CXCR3, the receptor for CXCL10, CXCL9 and CXCL11, showed increased survival, 
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decreased lung inflammation and less invasion following infection, depending on pneumococcal 
inoculation strain used 47. Moreover, addition of exogenous CXCL10 prior to infection of mice with 
influenza or respiratory syncytial virus (RSV) increased pneumonia severity 48. 
Our results support previous findings from murine models showing that CCL2 signalling and 
monocyte recruitment are key mediators of pneumococcal carriage clearance 16. However, contrary 
to key mechanisms described in murine models, we did not observe any production of IL-17A or 
neutrophil recruitment to the nose following carriage or associated with carriage clearance 15-17, 
underlining the importance of confirmation of murine findings by human data. 
One limitation of this study is that only one pneumococcal serotype 6B isolate was used, future 
studies using other isolates with a more or less invasive phenotype will be able to answer how 
generalizable these findings across pneumococcal isolates are. Nonetheless, the observation that 
carriage load and duration declines in parallel for all serotypes following repeated exposure, 
suggests that immunological control of newly-acquired Spn is mediated by similar mechanisms 
independent of the colonizing serotype 49.   
In conclusion, this study highlighted the importance of innate immunity in the control of carriage load 
and clearance of Spn, which was impaired by pre-existing viral infections.  Secondary bacterial 
infection following viral respiratory tract infection has a large burden of disease worldwide and 
disrupting viral-bacterial synergy through host-directed therapy could prove an attractive addition to 
current therapeutic and vaccination options 50. 
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Figure 1. LAIV-pneumococcus co-infection leads to excessive pro-inflammatory responses that 
associate with increased pneumococcal load and impaired monocyte recruitment. a) Experimental 
design of the study. LAIV = live attenuated influenza vaccine, Spn = Streptococcus pneumoniae. 
Analysed timepoints are indicated by black circles. b) Heatmap showing for each cytokine the 
median log2 fold-change compared to baseline for the timepoints 0/2/7/9, n = 19 per group. c) The 
delta in median log2 fold change (FC) following LAIV vaccination just prior to inoculation with Spn for 
subjects becoming carriage+ or carriage– (excluding subjects becoming positive by PCR only, who 
resemble subjects that become carriage+ by culture as well). The colour of each bar represents the 
median induction in the entire LAIV group. ** P = 0.0097 by two-tailed Wilcoxon test for LAIV 
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carriage– subjects comparing IL-10 day 0 to baseline, p = 0.073 for the LAIV carriage+ group. *** P 
= 0.0008 by two-tailed Wilcoxon test for LAIV carriage+ subjects comparing CXCL10 day 0 to 
baseline, p = 0.051 for the LAIV carriage– group. d) Pneumococcal load (median and interquartile 
range of CFU/mL nasal wash shown) for all carriage+ subjects with high (top quartile, n = 9) or low 
(all subjects below top quartile, n = 28) CXCL10 concentrations at day 0. P = 0.019 by two-tailed 
Mann-Whitney of AUC of log-transformed load over time.  e) Scatter plot showing correlation of 
CXCL10 concentration at baseline with Spn load for a second validation cohort (n = 52) with an 
asymptomatic upper respiratory tract virus infection (n=15) or not. Spearman correlation test results 
and linear regression line with 95% confidence interval (grey shading) are shown.  
Figure 2. Neutrophil function is impaired following LAIV administration. a) Concentrations of 
myeloperoxidase (MPO) in nasal wash (NW) of volunteers before or 2 days post Spn inoculation. 
Median and interquartile range are shown (for n=9 LAIV carriage– and LAIV carriage+ and for n=10 
control carriage– and control carriage+ subjects). * P = 0.014 by two-tailed Wilcoxon paired test. b) 
Spn opsonophagocytic killing (OPK) capacity of blood neutrophils before and 3 days following LAIV 
(n=6) or control (TIV or no, n=7) vaccination. Individual subjects are shown and connected by lines. 
*P = 0.031 by two-tailed Wilcoxon paired test. c) Effect of exogenous TNF (n=10) and d) CXCL10  
(n=8) on OPK activity of blood neutrophils of healthy volunteers. ** P = 1.15x10-5 by Friedman test. 
Neutrophils from 6 subjects were used in 3 independent experiments. Individual samples are 
depicted and connected by dashed lines.  e) Normalized MAP4K2 and TIGIT counts on sorted 
neutrophils before LAIV or in control arm (n=6, red) and following LAIV (n=4, blue). Individual 
samples are shown and paired samples are connected by black lines. ** P = 0.008 and *** p = 
3.2x10-5 two-tailed unadjusted p-values using  negative binomial generalized linear model (DESeq2). 
f) Correlation between OPK activity and TIGIT counts (n=10). Spearman rho and p-value are shown. 
Regression line and 95% confidence intervals (shaded area) are shown. g) Levels of TIGIT on blood 
neutrophil surface measured by flow cytometry after a 30 minute incubation without or with 1ng/mL 
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TNF or 100ng/mL TNF (n=4). *P = 0.042 by Friedman test. Individual subjects are depicted by dots 
and connected by lines. 
Figure 3. Monocyte recruitment following pneumococcal colonization is impaired during LAIV co-
infection. a) Median and interquartile range of nasal monocyte numbers normalized to epithelial cell 
numbers are shown for control carriage+ (n=24), control carriage– (n=37), LAIV carriage+ (n=25) 
and LAIV carriage– (n=30) groups. The dashed green line shows the baseline level in the control 
carriage+ group. *P = 0.038  at day 2 and p = 0.030 at day 29, **p = 0.002 by two-tailed Wilcoxon 
paired non-parametric test. Levels of maximum pneumococcal (Spn) load are shown for the b) 
Control (n=22) and c) LAIV group (n=23) and correlated with the maximum monocyte recruitment 
(fold change to baseline). Individual subjects are shown and Spearman correlation analysis is 
shown.  
Figure 4. Pneumococcus-specific responses are induced following colonization, which is impaired 
by LAIV co-infection. a) Whole nasal cells were collected 28 days post-inoculation and stimulated 
for 18 hours with heat-killed Spn for 48 subjects. Supernatant was collected and concentrations of 
30 cytokines were measured by multiplex ELISA. The median and interquartile range for cytokines 
induced at least 2-fold in at least one condition are displayed. b) Correlations between cytokine 
production following Spn stimulation and pneumococcal load are shown (n=22). Spearman non-
parametric correlation test results and regression lines with shaded 95% confidence intervals are 
shown per cytokine. c) The cytokine profile from alveolar macrophages (median for 6 volunteers 
shown) exposed to Spn for 18 hours was compared with that of stimulated whole nasal cells (median 
of control carriage+ group shown). Spearman non-parametric correlation test results and a 
regression lines with shaded 95% confidence intervals are shown. 
Figure 5. Nasal transcriptomics following LAIV-Spn co-infection (n=35). a) The number of 
differentially expressed genes (DEGs) between each time point and the baseline for each group are 
shown. Upregulated and downregulated genes are depicted in red and blue, respectively. 
Connections between bars show the number of common genes between LAIV and control conditions 
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where colors reflect distinct pathways. b) Circular representation of DEG and Gene Set Enrichment 
Analysis (GSEA) for LAIV carriage+ and control carriage+ groups at day 2 and day 9 to Spn 
inoculation. The individual log2-fold changes (baseline-normalized values) values were used as 
ranks in a single sample GSEA analysis to identify consistently enriched pathways among subjects. 
Genes and pathways are connected by lines. 
Figure 6. CEMiTool applied to control cohort – Module 1. Raw counts were normalized using log 
counts per million (CPM) and log2-fold change were calculated for each timepoint against the 
baseline after which co-expression modules were extracted. a) Gene Set Enrichment Analyses 
showing the module activity on each timepoint for carriage+ and carriage– groups. b) Correlation 
with average fold change counts of all M1 genes at day 9 with paired numbers of monocytes from 
the volunteer’s other nostril. Individual subjects, regression line with 95% confidence interval and 
Spearman correlation analysis are shown (n=13). c) The genes of module M1 present with genes 
highly expressed in CD14+CD16- (578 genes), CD14+CD16+ (108 genes), CD14-CD16+ (162 
genes), showing the overlapping number of genes between M1 and monocyte subsets in 
parentheses. The overlap for significance we analysed using the Chi-square test. d) Over 
Representation Analysis of module M1 using gene sets from the Reactome Pathway database. e) 
Interaction plot for M1, with gene nodes highlighted. 
Figure 7. CEMiTool applied to control group – M3. Raw counts were normalized using logCPM and 
log2-fold change were calculated for each timepoint against the baseline after which co-expression 
modules were extracted. a) Over Representation Analysis of module M3 of the control group using 
gene sets from the Reactome Pathway database. e) Interaction plot for M3, with gene nodes 
highlighted.  
Figure 8. CEMiTool applied to LAIV. Raw counts were normalized using logCPM and log2-fold 
change were calculated for each timepoint against the baseline after which co-expression modules 
were extracted. a) Gene Set Enrichment Analyses showing the module activity on each timepoint 
for carriage+ and carriage– LAIV groups. b) Over Representation Analysis of module M5 of the 
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LAIV group using gene sets from the Reactome Pathway database. e) Interaction plot for M5, with 
gene nodes highlighted.  
 
Methods 
Additional information on data reporting can be found in the Life Sciences Reporting Summary. 
Study design and sample collection 
Healthy adult volunteers were 1:1 randomized to receive either intranasally LAIV (2015/2016 Fluenz 
Tetra or FluMist Tetra, AstraZeneca, UK) or intramuscular Quadrivalent Inactivated Influenza 
Vaccination (Fluarix Tetra, GlaxoSmithKline, UK) as described previously 14. The control group also 
received a nasal saline spray, while the LAIV group also received a intramuscular saline injection. 
Three days post vaccination all subjects were inoculated with 80,000 CFU per nostril of 6B type Spn 
as described 6,51. Nasal microbiopsies (ASL Rhino-Pro©, Arlington Scientific) and nasal lining fluid 
(Nasosorption™, Hunt Developments) samples were collected and stored at -80C as previously 
described 52.  
 
Clinical Trial details 
The double-blinded randomized clinical LAIV-EHPC trial was registered on EudraCT (Number 2014-
004634-26) on 28th April 2015 and ISRCTN (Number 16993271) on 2nd Sep 2015 and was co-
sponsored by the Royal Liverpool University Hospital and the Liverpool School of Tropical Medicine. 
Key eligibility criteria included: capacity to give informed consent, no immunocompromised state or 
contact with susceptible individuals, no pneumococcal or influenza vaccine or infection in the last 
two years and not having taken part in EHPC studies in the past three years. The primary endpoint 
was the occurrence of pneumococcal colonisation determined by the presence of pneumococcus in 
nasal wash samples (NW) at any time point post inoculation up to and including day 29, detected 
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using classical microbiology or lytA qPCR as described 6,51,53. In this study, 130 volunteers were 
inoculated with pneumococcus, giving an 80% power to identify a 50% increase in carriage 
acquisition. Of 130 vaccinated volunteers, five were natural pneumococcal carriers (two in LAIV arm 
and three in control arm) and were excluded from further analysis. Another 8 subjects in the LAIV 
arm were excluded following a systematic LAIV dispensing error by a single practitioner, as 
recommended by the trial steering group. This resulted in a final 55 subjects analysed in the LAIV 
arm and 62 subjects in the control arm. Key secondary endpoints included the load of pneumococcal 
colonisation in NW at each time point following pneumococcal inoculation (days 2, 7, 9, 14, 22 and 
29), detected using classical microbiology, the area under the curve of pneumococcal colonisation 
load following pneumococcal inoculation (days 2, 7, 9, 14 , 22 and 29), detected using classical 
microbiology or by molecular methods (lytA), and the immunological mechanisms associated with 
altered susceptibility to pneumococcus following LAIV. The outcomes reported in this manuscript 
were a priori included in the study protocol. 
 
Ethics statement 
All volunteers gave written informed consent and research was conducted in compliance with all 
relevant ethical regulations. Ethical approval was given by the East Liverpool NHS Research and 
Ethics Committee (REC)/Liverpool School of Tropical Medicine (LSTM) REC, reference numbers: 
15/NW/0146 and 14/NW/1460 and Human Tissue Authority licensing number 12548. 
 
Flow cytometry analysis 
Immunophenotyping of nasal cells obtained by curettes was performed as described 52. In brief, cells 
were dislodged from curettes and stained with LIVE/DEAD® Fixable Violet Dead Cell Stain 
(ThermoFisher) and an antibody cocktail containing Epcam-PE (9C4), HLADR-PECy7 (L243), 
CD16-APC (3G8), CD66b-FITC (G10F5, all Biolegend), CD3-APCH7 (SK7), CD14-PercpCy5.5 
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(MφP9, both BD Biosciences) and CD45-PACOrange (HI30, ThermoFisher). Whole blood was 
stained for 15 min at room temperature with TIGIT-PECy7 (A15153G, Biolegend) and CD16-APC, 
followed by 2x 10 min incubation steps with FACSLysis buffer (BD Biosciences) to remove 
erythrocytes. Samples were acquired on a LSRII flow cytometer (BD) and analysed using Flowjo X 
(Treestar). Fluorescent minus one controls for each of the included antibodies were used to validate 
results. For the LAIV and control cohorts, but not the additional validation cohort (Supplementary 
Fig. 5C), 84/553 samples (15.2%) with less than 500 immune cells or 250 epithelial cells were 
excluded from further analysis.  
 
Neutrophil opsonophagocytic killing 
Neutrophil killing capacity was evaluated as previously described with minor modifications 54. Briefly, 
neutrophils were isolated through density gradient centrifugation, followed by 45 min incubation with 
serotype 6B pneumococci (inoculation strain, MOI 100:1), baby rabbit complement (Mast Group, 
Bootle, UK) and human intravenous immunoglobulin (IVIG; Gamunex, Grifols Inc, Spain). In some 
experiments, recombinant TNF or CXCL10 (Biotechne) was added.  
 
Luminex analysis of nasal lining fluid or stimulated nasal cells 
 Nasal cells collected in RPMI containing 1% penicillin/streptomycin/neomycin (ThermoFisher) and 
10% heat-inactivated FBS (ThermoFisher) were incubated with 50ug/mL DNAse I (Sigma Aldrich) 
at room temperature for 20 min and filtered over a 70um filter (ThermoFisher).  Cells were spun 
down at 440xg for 5 min, resuspended, counted and incubated at 250,000 cells/mL in 96-wells or 
384-wells plates (ThermoFisher). Heat-killed Spn inoculation strain was added at a concentration of 
5 µg/mL of total protein (corresponding to 4.3x10^7 CFU/mL) and cells were incubated for 18 h. 
Bacterial protein concentration was measured by Bradford assay, using bovine serum albumin as 
standard and titration experiments were performed to determine dose. Supernatant was collected 
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and stored at -80C until analysis. For nasosorption filters, cytokines were eluted from stored filters 
using 100 uL of assay buffer (ThermoFisher) by centrifugation, then the eluate was cleared by further 
centrifugation at 16,000g. Prior to analysis, samples were centrifuged for 10 min at 16,000xg to clear 
samples. These were acquired on a LX200 using a 30-plex magnetic human Luminex cytokine kit 
(ThermoFisher) and analysed with xPonent3.1 software following manufacturer’s instructions. 
Samples were analysed in duplicates and nasosorption samples with a CV > 25% were excluded. 
 
RNA extraction and sequencing 
Nasal cells were collected in RNALater (ThermoFisher) at -80C until extraction. Extraction was 
performed using the RNEasy micro kit (Qiagen) with on column DNA digestion. Extracted RNA was 
quantified using a Qubit™ (ThermoFisher). Sample integrity assessment (Bioanalyzer, Agilent), 
library preparation and RNA-sequencing (Illumina Hiseq4000, 20M reads, 100 paired-end reads) 
were performed at the Beijing Genome Institute (China).  
 
Nanostring 
Purified blood neutrophils were stored in RLT buffer (Qiagen) with 1% 2-mercaptoethanol (Sigma) 
at -80C until RNA extraction as above. The single cell immunology v2 kit (Nanostring) was used with 
20 pre-amp cycles for all samples. Hybridized samples were prepared on a Prep Station and 
scanned on a nCounter® MAX (Nanostring). Raw counts were analysed using DESeq2 using 
internal normalization, which gave lower variance than normalizing to included housekeeping genes. 
DEG were identified using a model matrix correcting for repeated individual measurements.  
 
RNA sequencing analysis 
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Quality control of raw sequencing data was done using fastQC. Mapping to a human reference 
genome assembly (GRCh38) was done using STAR 2.5.0a 55. Read counts from the resulting BAM 
alignment files were obtained with featureCounts using a GTF gene annotation from the Ensembl 
database 56,57. The R/Bioconductor package DESeq2 was used to identify differentially expressed 
genes among the samples, after removing absent features (zero counts in more than 75% of 
samples) 58. Genes with an FDR value < 0.1 and an absolute fold change (FC) > 1.5 were identified 
as differentially expressed.  
 
Co-expression analysis 
For co-expression analysis, counts were normalized using log CPM and the log2 fold change was 
calculated for each time point in a subject-wise manner. The co-expression analysis was performed 
separately for each group (control and LAIV) using the CEMiTool package developed by our group 
and available at Bioconductor (https://bioconductor.org/packages/release/bioc/html/CEMiTool.html) 
39. This package unifies the discovery and the analysis of coexpression gene modules, evaluating if 
modules contain genes that are over-represented by specific pathways or that are altered in a 
specific sample group. A p-value = 0.05 was applied for filtering lowly expressed genes. 
 
Statistical analysis 
All experiments were performed randomised and blinded. Two-tailed statistical tests are used 
throughout the study. When log-normalized data was not normally distributed, non-parametric tests 
were performed and multiple correction testing (Benjamin-Hochberg) was applied for gene 
expression and Luminex analysis.  
 
Data availability statement 
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Raw RNA-sequencing data have been deposited in the GEO repository, accession number 
GSE117580. All other underlying data is provided in the manuscript. 
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